Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Uniunea Europeană - română - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresoare - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

ERLOTINIB KRKA 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib krka 100 mg

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB KRKA 150 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib krka 150 mg

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB KRKA 25 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib krka 25 mg

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza

ROSUVASTATINA KRKA 5 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 5 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 5mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

ROSUVASTATINA KRKA 10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 10 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 10mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

ROSUVASTATINA KRKA 15 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 15 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 15mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

ROSUVASTATINA KRKA 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 20 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 20mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

ROSUVASTATINA KRKA 30 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 30 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 30mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

ROSUVASTATINA KRKA 40 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rosuvastatina krka 40 mg

krka d.d. novo mesto - slovenia - rosuvastatinum - compr. film. - 40mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei